Compstatin TFA ethyl-5-methoxy-phenol 1-O-β-d-glucopyranosyl-(1 → 6)-β-d-glucopyranoside S)-AHPC-C4-NH2 dihydrochloride is a synthesized

S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S

WO2019195609A2

Insulin-stimulated translocation of ARF6 to the plasma membrane is also inhibited by SecinH3

CGK733 (10 μM) causes the loss of cyclin D1 through the ubiquitin-dependent proteasomal degradation pathway in MCF-7 and T47D breast cancer cell lines

ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase

Compstatin TFA ethyl-5-methoxy-phenol 1-O-β-d-glucopyranosyl-(1 → 6)-β-d-glucopyranoside S)-AHPC-C4-NH2 dihydrochloride is a synthesizedCompstatin TFA, a 13 residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates complement system. Compstatin TFA exhibits IC50 values of 63 M and 12 M for classical and alterative complement pathway, respectively. Product information Molecular